


Appendix A

Claim Amendments

1. (Currently amended) Compounds A compound of formula 1



in which

R1 is phenyl,

phenyl substituted by R3 and/or R4,

naphthalenyl,

naphthalenyl substituted by R5 and/or R6,

aryl1,

aryl1 substituted by R7 and/or R8,

R9,

R10 or

R11,

R2 is phenyl,

phenyl substituted by R12 and/or R13,


naphthalenyl,

naphthalenyl substituted by R14 and/or R15,

aryl2,

aryl2 substituted by R16 and/or R17

or a radical selected from



R3 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-

yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy,  
1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-  
azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-  
4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy,  
-(CH<sub>2</sub>)<sub>n</sub>-N(R31)R32, -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R31)R32 or -O-(CH<sub>2</sub>)<sub>m</sub>-  
N(R31)R32 wherein

R31 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl,  
and

R32 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl  
or wherein

R31 and R32 together and with inclusion of the nitrogen  
atom to which they are bonded form a pyrrolidin-,  
piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-  
4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-  
[1,4]diazepan-, morpholin-, thiomorpholin- or an  
azepan-ring,

n is an integer from 0 to 4,

m is an integer from 2 to 4,

R4 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl,  
1-4C-alkoxy or 1-4C-alkoxy completely or predominantly  
predominately substituted by fluorine, amino or mono- or  
di-1-4C-alkylamino,

R5 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, -(CH<sub>2</sub>)<sub>n</sub>-N(R31)R32, -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R31)R32 or -O-(CH<sub>2</sub>)<sub>m</sub>-N(R31)R32,

R6 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly


predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

Aryl1 is furanyl, thiophenyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxaliny1, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl or dibenzofuranyl, R7 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-

yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy,  
1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-  
azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-  
4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy,  
-(CH<sub>2</sub>)<sub>n</sub>-N(R31)R32, -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R31)R32 or -O-(CH<sub>2</sub>)<sub>m</sub>-  
N(R31)R32,

R8 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl,  
1-4C-alkoxy or 1-4C-alkoxy completely or predominantly  
predominately substituted by fluorine, amino or mono- or  
di-1-4C-alkylamino,

R9 is unsubstituted pyrrolyl, pyrazolyl, imidazolyl,  
indolyl, indazolyl, benzimidazolyl or benztriazolyl, or  
a radical selected from




wherein

R91 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy

completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, -(CH<sub>2</sub>)<sub>n</sub>-N(R31)R32, -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R31)R32 or -O-(CH<sub>2</sub>)<sub>m</sub>-N(R31)R32,

R92 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R10 is a radical selected from




wherein

R101 is 1-4C-alkyl, 2,2,2-trifluoroethyl or 3,3,3-tri-  
fluoropropyl,

R102 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, tri-  
fluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or  
predominantly predominately substituted by fluorine,  
amino or mono- or di-1-4C-alkylamino,

R11 is a radical selected from



wherein

R111 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, -(CH<sub>2</sub>)<sub>p</sub>-N(R112)R113 or -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R112)R113, wherein R112 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and

R113 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, or wherein

R112 and R113 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

p is an integer from 1 to 4,

R114 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

Aryl2 is furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl,

2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl,

quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl,

phthalazinyl, indanyl, indolyl or indazolyl,

R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or ~~predominantly~~ predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, and the salts of these compounds or a salt thereof, with the proviso that the following compounds are excluded

4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N- {4- [6- (Bis-trifluoromethyl-phenyl) -pyrimidin-4-ylamino] - phenyl }-4-methyl-benzenesulfonamide.

4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide.

4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide.

N-{4-[6-(2-Benzyl-oxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-  
4-methyl-benzenesulfonamide,

N-{4-[6-(4-Benzyl-oxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-  
4-methyl-benzenesulfonamide,

N-{4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-  
phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-  
methyl-benzenesulfonamide,

N-(3-{6-[4-(Toluene-4-sulfonylamino)-phenylamino]-  
pyrimidin-4-yl}-phenyl)-acetamide,

N-{4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-  
methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-  
phenyl}-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-  
ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-  
methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-  
ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-  
methyl-benzenesulfonamide,

N- { 4- [ 6- ( 3-Dimethylamino-phenyl ) -pyrimidin-4-ylamino ] -  
phenyl } -4-methyl-benzenesulfonamide,  
N- [ 4- ( 6-Benzo[1, 3]dioxol-5-yl-pyrimidin-4-ylamino ) -phenyl ] -  
4-methyl-benzenesulfonamide,  
4-Methyl-N- [ 4- ( 6-pyridin-4-yl-pyrimidin-4-ylamino ) -phenyl ] -  
benzenesulfonamide,  
N- [ 4- ( 2', 4'-Dimethoxy-[4, 5']bipyrimidinyl-6-ylamino ) -  
phenyl ] -4-methyl-benzenesulfonamide,  
4-Methyl-N- [ 4- ( 6-pyridin-3-yl-pyrimidin-4-ylamino ) -phenyl ] -  
benzenesulfonamide,  
N- [ 4- ( 6-Benzofuran-2-yl-pyrimidin-4-ylamino ) -phenyl ] -4-  
methyl-benzenesulfonamide,  
4-Methyl-N- [ 4- ( 6-thiophen-3-yl-pyrimidin-4-ylamino ) -  
phenyl ] -benzenesulfonamide,  
N- [ 4- ( 6-Dibenzofuran-4-yl-pyrimidin-4-ylamino ) -phenyl ] -4-  
methyl-benzenesulfonamide,  
N- [ 4- ( 6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino ) -phenyl ] -  
4-methyl-benzenesulfonamide, and  
4-Methyl-N- [ 4- ( 6-quinolin-8-yl-pyrimidin-4-ylamino ) -  
phenyl ] -benzenesulfonamide.

2. (Currently amended) Compounds A compound of formula 1  
according to claim 1 in which

R1 is phenyl,

phenyl substituted by R3 and/or R4,

naphthalenyl or

naphthalenyl substituted by R5 and/or R6,

R2 is phenyl,

phenyl substituted by R12 and/or R13,


naphthalenyl,

naphthalenyl substituted by R14 and/or R15,

aryl2,

aryl2 substituted by R16 and/or R17

or a radical selected from



R3 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl,

aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy or benzyloxy,

R4 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R5 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy or benzyloxy,

R6 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or

predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, Aryl2 is furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl, R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted

by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-  
1-4C-alkylamino,

R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, and ~~the salts of these compounds or a salt thereof~~, with the proviso that the following compounds are excluded

4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-{4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-{4-[6-(2-Benzylxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Benzylxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,  
N-(3-{6-[4-(Toluene-4-sulfonylamino)-phenylamino]-pyrimidin-4-yl}-phenyl)-acetamide,  
N-{4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,  
4-Methyl-N-{4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-phenyl}-benzenesulfonamide,  
4-Methyl-N-{4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-benzenesulfonamide,  
N-{4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,  
4-Methyl-N-{4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-ylamino]-phenyl}-benzenesulfonamide,  
N-{4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide, and  
N-{4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide.

3. (Currently amended) Compounds A compound of formula 1 according to claim 1 in which

R1 is phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3-

acetylphenyl, 4-acetylphenyl, 3-cyanophenyl, 4-phenoxyphenyl or naphthalen-1-yl,

R2 is phenyl, phenyl substituted by R12 and/or R13, thiophenyl, naphthalenyl or 5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-yl,

R12 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine or 1-4C-alkoxycarbonyl,

R13 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

~~and the salts of these compounds or a salt therof~~, with the proviso that the following compounds are excluded

4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide, and

N-{4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide.

4. (Currently amended) Compounds A compound of formula 1 according to claim 1 in which

R1 is phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-acetylphenyl or naphthalen-1-yl,

R2 is 2-fluorophenyl, 3-fluorophenyl, 3,4-difluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluorophenyl, 3-chloro-4-methylphenyl, 3-bromophenyl, 3-methylphenyl, 4-methylphenyl, 4-isopropylphenyl, 4-trifluoromethylphenyl, 4-methoxyphenyl, 4-cyanophenyl or 5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-yl,

~~and the salts of these compounds or a salt thereof~~, with the proviso that the following compounds are excluded

4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide and


4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide.

5. (Currently amended) Compounds A compound of formula 1 according to claim 1 in which

R1 is phenyl substituted by R3 and/or R4 or naphthalenyl substituted by R5 and/or R6,

R2 is phenyl,

phenyl substituted by R12 and/or R13,  
naphthalenyl,  
naphthalenyl substituted by R14 and/or R15,  
aryl2,  
aryl2 substituted by R16 and/or R17  
or a radical selected from



R3 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-

(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, -(CH<sub>2</sub>)<sub>n</sub>-N(R31)R32, -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R31)R32 or -O-(CH<sub>2</sub>)<sub>m</sub>-N(R31)R32, wherein

R31 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and R32 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl or wherein

R31 and R32 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

n is an integer from 0 to 4,

m is an integer from 2 to 4,

R4 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R5 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-

4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, -(CH<sub>2</sub>)<sub>n</sub>-N(R31)R32, -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R31)R32 or -O-(CH<sub>2</sub>)<sub>m</sub>-N(R31)R32,

R6 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,  
Aryl2 is furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl,

R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, and ~~the salts of these compounds or a salt thereof.~~

6. (Currently amended) Compounds A compound of formula 1 according to claim 1 in which

R1 is phenyl substituted in para or meta position by R3 or phenyl substituted in para and meta position by R3 and R4,

R2 is phenyl substituted by R12 and/or R13,

R3 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-

azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-  
1-4C-alkoxy, -(CH<sub>2</sub>)<sub>n</sub>-N(R31)R32, -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R31)R32 or  
-O-(CH<sub>2</sub>)<sub>m</sub>-N(R31)R32, wherein

R31 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and  
R32 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl or  
wherein

R31 and R32 together and with inclusion of the nitrogen atom  
to which they are bonded form a pyrrolidin-,  
piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-  
4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-  
[1,4]diazepan-, morpholin-, thiomorpholin- or an  
azepan-ring,

n is an integer from 1 to 4,

m is an integer from 2 to 4,

R4 is fluorine, methyl or methoxy,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl,  
trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is  
completely or predominantly predominately substituted  
by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-  
1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-  
alkoxy, 1-4C-alkoxy which is completely or

~~predominantly predominately~~ substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, and the salts of these compounds or a salt thereof.

7. (Currently amended) ~~Compounds~~ A compound of formula 1

according to claim 1 in which

- R1 is phenyl substituted in para or meta position by R3,  
R2 is phenyl substituted by R12 and/or R13,  
R3 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, -(CH<sub>2</sub>)<sub>n</sub>-N(R31)R32, -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R31)R32 or -O-(CH<sub>2</sub>)<sub>m</sub>-N(R31)R32, wherein  
R31 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and

R32 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl  
or wherein

R31 and R32 together and with inclusion of the nitrogen  
atom to which they are bonded form a pyrrolidin-,  
piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-  
4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-  
[1,4]diazepan-, morpholin-, thiomorpholin- or an  
azepan-ring,

n is an integer from 1 to 4,

m is an integer from 2 to 4,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl,  
trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is  
completely or predominantly predominately substituted  
by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-  
1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-  
alkoxy, 1-4C-alkoxy which is completely or  
predominantly predominately substituted by fluorine, 1-  
4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,  
~~and the salts of these compounds or a salt thereof.~~

8. (Currently amended) Compounds A compound of formula 1  
according to claim 1 in which

R1 is phenyl substituted in para position by R3 or phenyl substituted in para position by R3 and in meta position by R4,

R2 is phenyl substituted by R12 and/or R13,

R3 is morpholin-4-ylmethyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, 2-morpholin-4-ylethoxy, 3-morpholin-4-ylpropoxy, 4-methylpiperazin-1-ylmethyl, 4-methylpiperazin-1-ylethyl, 4-methylpiperazin-1-ylpropyl, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 1-methylpiperidin-4-ylmethoxy, 1-methylpiperidin-4-ylmethoxy, 1-methylpiperidin-4-ylethyl, 1-methylpiperidin-4-ylpropyl, 2-(1-methylpiperidin-4-yl)ethoxy, 3-(1-methylpiperidin-4-yl)propoxy, pyrrolidin-1-ylpropyl, pyrrolidin-1-ylethyl, pyrrolidin-1-ylmethyl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-ylethoxy, piperidin-1-ylmethyl, piperidin-1-ylethyl, piperidin-1-ylpropyl, 2-(piperidin-1-yl)ethoxy, 3-(piperidin-1-yl)propoxy,

R4 is fluorine, methyl or methoxy,

R12 is fluorine, chlorine, cyano, methyl, isopropyl, trifluoromethyl or methoxy,

R13 is fluorine or chlorine,

~~and the salts of these compounds or a salt thereof.~~

9. (Currently amended) Compounds A compound of formula 1

according to claim 1 in which

R1 is phenyl substituted in para or meta position by R3,  
R2 is phenyl substituted by R12 and/or R13,  
R3 is morpholin-4-ylmethyl, morpholin-4-yethethyl, morpholin-  
4-ylpropyl, 2-morpholin-4-yethoxy, 3-morpholin-4-  
ylpropoxy, 4-methylpiperazin-1-ylmethyl, 4-  
methylpiperazin-1-yethethyl, 4-methylpiperazin-1-ylpropyl,  
2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-  
1-yl)propoxy, 1-methylpiperidin-4-ylmethoxy, 1-  
methylpiperidin-4-ylmethyl, 1-methylpiperidin-4-yethethyl,  
1-methylpiperidin-4-ylpropyl, 2-(1-methylpiperidin-4-  
yl)ethoxy, 3-(1-methylpiperidin-4-yl)propoxy,  
pyrrolidin-1-ylpropyl, pyrrolidin-1-yethethyl, pyrrolidin-  
1-ylmethyl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-  
yethoxy, piperidin-1-ylmethyl, piperidin-1-yethethyl,  
piperidin-1-ylpropyl, 2-(piperidin-1-yl)ethoxy, 3-  
(piperidin-1-yl)propoxy,  
R12 is fluorine, chlorine, cyano, methyl, isopropyl,  
trifluoromethyl or methoxy,  
R13 is fluorine or chlorine,  
~~and the salts of these compounds or a salt thereof.~~

10. (Currently amended) Compounds A compound of formula 1 according to claim 1 in which

R1 is phenyl substituted in para position by R3 or phenyl substituted in para position by R3 and in meta position by R4,

R2 is 2-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl, 2,4-difluorophenyl, 2-fluoro-4-methylphenyl, 2-fluoro-4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methylphenyl, 4-methoxyphenyl or 3-chloro-4-fluorophenyl,

R3 is 2-morpholin-4-yloxy, 3-morpholin-4-ylpropoxy, 4-methylpiperazin-1-yloxy, 4-methylpiperazin-1-ylpropoxy, morpholin-4-ylmethyl, morpholin-4-yethyl, morpholin-4-ylpropyl, 1-methylpiperidin-4-ylmethoxy, 2-(1-methylpiperidin-4-yl)ethoxy, 4-methylpiperazin-1-yethyl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-yloxy or 3-pyrrolidin-1-ylpropyl,

R4 is fluorine,

~~and the salts of these compounds or a salt thereof.~~

11. (Currently amended) Compounds A compound of formula 1 according to claim 1 in which

R1 is phenyl substituted in para or meta position by R3,

R2 is 2-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl,  
2,4-difluorophenyl, 4-methylphenyl, 4-methoxyphenyl or  
3-chloro-4-fluorophenyl,  
R3 is 2-morpholin-4-yethoxy, 3-morpholin-4-ylpropoxy, 4-  
methylpiperazin-1-yethoxy, 4-methylpiperazin-1-  
ylpropoxy, morpholin-4-ylmethyl, morpholin-4-ylethyl,  
morpholin-4-ylpropyl, 1-methylpiperidin-4-ylmethoxy, 2-  
(1-methylpiperidin-4-yl)ethoxy, 4-methylpiperazin-1-  
ylethyl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-  
yethoxy or 3-pyrrolidin-1-ylpropyl,

~~and the salts of these compounds or a salt thereof.~~

**12. (Currently amended) Compounds A compound of formula 1**

according to claim 1 in which

R1 is aryl1,

aryl1 substituted by R7 and/or R8,

R9 or

R10,

R2 is phenyl,

phenyl substituted by R12 and/or R13,


naphthalenyl,

naphthalenyl substituted by R14 and/or R15,

aryl2,

aryl2 substituted by R16 and/or R17

or a radical selected from



Aryl1 is furanyl, thiophenyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxaliny, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl or dibenzofuranyl, R7 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-

pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-  
1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-  
(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-  
azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-  
alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-  
alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-  
pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-  
yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy,  
1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-  
azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-  
4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy,  
- (CH<sub>2</sub>)<sub>n</sub>-N(R31)R32, -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R31)R32 or -O-(CH<sub>2</sub>)<sub>m</sub>-  
N(R31)R32, wherein

R31 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and  
R32 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl or  
wherein


R31 and R32 together and with inclusion of the nitrogen atom  
to which they are bonded form a pyrrolidin-,  
piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-  
4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-  
[1,4]diazepan-, morpholin-, thiomorpholin- or an  
azepan-ring,

n is an integer from 0 to 4,

m is an integer from 2 to 4,

R8 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R9 is unsubstituted pyrrolyl, pyrazolyl, imidazolyl, indolyl, indazolyl, benzimidazolyl or benztriazolyl, or a radical selected from




wherein

R91 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-

1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, -(CH<sub>2</sub>)<sub>n</sub>-N(R31)R32, -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R31)R32 or -O-(CH<sub>2</sub>)<sub>m</sub>-N(R31)R32,

R92 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R10 is a radical selected from



wherein

R101 is 1-4C-alkyl, 2,2,2-trifluoroethyl or 3,3,3-trifluoropropyl,

R102 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

Aryl2 is furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl,

R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, ~~and the salts of these compounds or a salt thereof~~ with the proviso that the following compounds are excluded

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide, and

4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide.

13. (Currently amended) Compounds A compound of formula 1 according to claim 1 in which

R1 is pyrid-3-yl, pyrid-4-yl, 2-methyl-2,3-dihydrobenzofuran-5-yl, benzo[1,3]dioxol-5-yl, 1-methyl-1H-pyrrol-3-yl, 4-methyl-thiophen-2-yl, 1-methyl-1H-pyrrol-2-yl, 1H-indol-5-yl, 1-methyl-1H-indol-3-yl, 1-methyl-1H-indol-5-yl, dibenzofuran-4-yl or 3,5-dimethyl-isoxazol-4-yl,

R2 is phenyl substituted by R12 and/or R13 or naphthalenyl,  
R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl,

trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, and ~~the salts of these compounds or a salt thereof with the~~ proviso that the following compounds are excluded

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-

4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-  
benzenesulfonamide, and

4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-  
benzenesulfonamide.

**14.** (Currently amended) Compounds A compound of formula 1

according to claim 1 in which

R1 is 2-methyl-2,3-dihydrobenzofuran-5-yl, benzo[1,3]-  
dioxol-5-yl, 1-methyl-1H-pyrrol-3-yl, 4-methyl-thiophen-  
2-yl, 1-methyl-1H-pyrrol-2-yl, 1H-indol-5-yl, 1-methyl-  
1H-indol-3-yl or 1-methyl-1H-indol-5-yl,

R2 is phenyl substituted by R12 and/or R13 or naphthalenyl,

R12 is fluorine, chlorine, cyano, methyl, trifluoromethyl or  
methoxy,

R13 is fluorine, chlorine or methoxy,

~~and the salts of these compounds or a salt thereof~~ with the  
proviso that the compound

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-  
4-methyl-benzenesulfonamide is excluded.

**15.** (Currently amended) Compounds A compound of formula 1

according to claim 1 in which

R1 is 2-methyl-2,3-dihydrobenzofuran-5-yl, 1-methyl-1H-pyrrol-3-yl or 4-methylthiophen-2-yl, and

R2 is 2,6-difluorophenyl,

or

R1 is 1H-indol-5-yl, and

R2 is 2,6-difluorophenyl, 2,4-difluorophenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl or 3-fluorophenyl,

or

R1 is 1-methyl-1H-indol-5-yl or 1-methyl-1H-indol-3-yl, and

R2 is 2,6-difluorophenyl, 2-fluorophenyl or 4-methoxyphenyl,

or

R1 is 1-methyl-1H-indol-5-yl, and

R2 is 2-fluoro-4-methylphenyl,

~~and the salts of these compounds or a salt thereof.~~

**16.** (Currently amended) Compounds A compound of formula 1

according to claim 1 in which

either

R1 is 2-methyl-2,3-dihydrobenzofuran-5-yl, 1-methyl-1H-pyrrol-3-yl or 4-methylthiophen-2-yl, and

R2 is 2,6-difluorophenyl,

or

R1 is 1H-indol-5-yl, and

R2 is 2,6-difluorophenyl, 2,4-difluorophenyl, 2-fluorophenyl or 3-fluorophenyl,

or

R1 is 1-methyl-1H-indol-5-yl or 1-methyl-1H-indol-3-yl, and

R2 is 2,6-difluorophenyl, 2-fluorophenyl or 4-methoxyphenyl,

~~and the salts of these compounds or a salt thereof.~~

**17.** (Currently amended) Compounds A compound of formula 1

according to claim 1 in which

R1 is R11,

R2 is phenyl,

phenyl substituted by R12 and/or R13,


naphthalenyl,

naphthalenyl substituted by R14 and/or R15,


aryl2,

aryl2 substituted by R16 and/or R17

or a radical selected from



R111 is a radical selected from



wherein

R111 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, -(CH<sub>2</sub>)<sub>p</sub>-N(R112)R113 or -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R112)R113, wherein R112 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl,

and

R113 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, or wherein

R112 and R113 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

p is an integer from 1 to 4,

R114 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly predominately substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,  
Aryl2 is furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl,

R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,






R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, and the salts of these compounds or a salt thereof.

**18.** (Currently amended) Compounds A compound of formula 1 according to claim 1 in which

R1 is R11,

R2 is phenyl substituted by R12 and/or R13,

R11 is a radical selected from



wherein

R111 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, or 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl.

3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl,  
-(CH<sub>2</sub>)<sub>p</sub>-N(R112)R113 or -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R112)R113, wherein  
R112 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl,  
and

R113 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, or  
wherein

R112 and R113 together and with inclusion of the nitrogen  
atom to which they are bonded form a pyrrolidin-,  
piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-  
4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-  
[1,4]diazepan-, morpholin-, thiomorpholin- or an  
azepan-ring,

p is an integer from 1 to 4,

R114 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl,  
trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely  
or predominantly predominately substituted by fluorine,  
amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl,  
trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is  
completely or predominantly predominately substituted  
by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-  
1-4C-alkylamino,


R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly predominately substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, and the salts of these compounds or a salt thereof.

**19.** (Currently amended) Compounds A compound of formula 1 according to claim 1 in which

R1 is R11,

R2 is phenyl substituted by R12 and/or R13,

R11 is a radical selected from



wherein

R111 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, -(CH<sub>2</sub>)<sub>p</sub>-N(R112)R113 or -CH<sub>2</sub>CH(OH)CH<sub>2</sub>N(R112)R113, wherein

R112 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl,  
and

R113 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, or  
wherein

R112 and R113 together and with inclusion of the nitrogen  
atom to which they are bonded form a pyrrolidin-,  
piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-  
4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-  
[1,4]diazepan-, morpholin-, thiomorpholin- or an  
azepan-ring,

p is an integer from 1 to 4,

R114 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl,  
trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely  
or predominantly predominately substituted by fluorine,  
amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl,  
trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is  
completely or predominantly predominately substituted  
by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-  
1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-  
alkoxy, 1-4C-alkoxy which is completely or


~~predominantly predominately~~ substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino, and the salts of these compounds or a salt thereof.

**20.** (Currently amended) Compounds A compound of formula 1 according to claim 1 in which

R1 is R11,

R2 is phenyl substituted by R12 and/or R13,

R11 is a radical selected from



wherein

R111 is pyrrolidin-1-ylethyl, pyrrolidin-1-ylpropyl, piperidin-1-ylethyl, piperidin-1-ylpropyl, azepan-1-ylethyl, azepan-1-ylpropyl, (4-methyl-piperazin-1-yl)ethyl, (4-methyl-piperazin-1-yl)propyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, (1-methyl-piperidin-4-yl)propyl, (1-methyl-piperidin-4-yl)ethyl, (1-methyl-piperidin-4-yl)methyl, dimethylaminoethyl, dimethylaminopropyl, dimethylaminobutyl,

diethylaminoethyl, diethylaminopropyl or

diethylaminobutyl,

R114 is hydrogen or fluorine,

R12 is fluorine, chlorine, cyano, methyl, isopropyl,

trifluoromethyl or methoxy,

R13 is fluorine or chlorine,

~~and the salts of these compounds or a salt thereof.~~


**21.** (Currently amended) Compounds A compound of formula 1

according to claim 1 in which

R1 is R11,

R2 is 2-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl,  
2,4-difluorophenyl, 4-methylphenyl, 4-methoxyphenyl, 3-  
fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, or 3-  
chloro-4-fluorophenyl,

R11 represents the following radical



wherein

R111 is pyrrolidin-1-ylethyl, pyrrolidin-1-ylpropyl, (4-methyl-piperazin-1-yl)ethyl, (4-methyl-piperazin-1-yl)propyl, (1-methyl-piperidin-4-yl)ethyl, (1-methyl-piperidin-4-

yl)methyl, dimethylaminoethyl, dimethylaminopropyl,  
diethylaminopropyl or diethylaminobutyl,  
~~and the salts of these compounds or a salt thereof.~~

**22.** (Canceled).

**23.** (Currently amended) A pharmaceutical composition comprising Pharmaceutical compositions containing one or more compounds according to claim 1, or a pharmaceutically acceptable salt thereof, together with the usual pharmaceutical auxiliaries and/or excipients a pharmaceutically acceptable auxiliary and/or excipient.

**24.** (Canceled)

**25.** (Currently amended) A method for treating acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vacular injury, such as angioplasty, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer Alzheimer's disease, [[or]] amyotrophic lateral sclerosis, cancer, infectious diseases, such as AIDS, septic shock [[or]] adult respiratory

distress syndrome, ischemia/reperfusion injury, [[e.g.]] myocardial infarction, stroke, gut ischemia, renal failure, [[or]] hemorrhage shock, [[or]] traumatic shock, T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma, [[or]] inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, and further eczematous dermatitis, seborrheic dermatitis dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, [[e.g.]] Sjogren's syndrome, keratoconjunctivitis, [[or]] uveitis, inflammatory bowel disease, Crohn's disease, [[or]] ulcerative colitis in a patient comprising administering to said patient a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

**26.** (Currently amended) A compound selected from the group consisting of

4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
N-{4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,  
4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
N-{4-[6-(2-Benzylxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,  
N-{4-[6-(4-Benzylxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,  
N-{4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,  
N-{4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,  
N-(3-{6-[4-(Toluene-4-sulfonylamino)-phenylamino]-pyrimidin-4-yl}-phenyl)-acetamide,  
N-{4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-phenyl}-benzenesulfonamide,  
4-Methyl-N-{4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-benzenesulfonamide,  
N-{4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,  
4-Methyl-N-{4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-ylamino]-phenyl}-benzenesulfonamide,  
N-{4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,  
N-{4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,  
N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,  
4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,  
4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,  
N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,  
4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
and salts thereof  
~~or a salt thereof for use in the treatment of diseases.~~

**27.** (Currently amended) A pharmaceutical composition comprising containing one or more compounds selected from the group consisting of

4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
N-[4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,  
4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-{4-[6-(2-Benzylxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-  
4-methyl-benzenesulfonamide,  
N-{4-[6-(4-Benzylxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-  
4-methyl-benzenesulfonamide,  
N-{4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-  
phenyl}-4-methyl-benzenesulfonamide,  
N-{4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-  
methyl-benzenesulfonamide,  
N-(3-{6-[4-(Toluene-4-sulfonylamino)-phenylamino]-  
pyrimidin-4-yl}-phenyl)-acetamide,  
N-{4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-  
methyl-benzenesulfonamide,  
4-Methyl-N-{4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-  
phenyl}-benzenesulfonamide,  
4-Methyl-N-{4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-  
ylamino]-phenyl}-benzenesulfonamide,  
N-{4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-  
methyl-benzenesulfonamide,  
4-Methyl-N-{4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-  
ylamino]-phenyl}-benzenesulfonamide,  
N-{4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-  
methyl-benzenesulfonamide,

N-{4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,  
N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,  
4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,  
4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,  
4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,  
N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,  
4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
and pharmaceutically acceptable salts or a salt thereof  
together with a pharmaceutically acceptable auxiliary

and/or excipient the usual pharmaceutical auxiliaries  
and/or excipients.

**28.** (Canceled)

**29.** (Currently amended) A method for treating acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vacular injury, such as angioplasty, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer Alzheimer's disease, [[or]] amyotrophic lateral sclerosis, cancer, infectious diseases, such as AIDS, septic shock [[or]] adult respiratory distress syndrome, ischemia/reperfusion injury, [[e.g.]] myocardial infarction, stroke, gut ischemia, renal failure, [[or]] hemorrhage shock, [[or]] traumatic shock, T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma, [[or]] inflammatory lung injury, inflammatory liver injury, inflammatory

glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, ~~inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, and further eczematous dermatitis, seborrheic dermatitis, seborrhoeic dermatitis, inflammatory eye diseases, [[e.g.]] Sjoegren's syndrome, keratoconjunctivitis, [[or]] uveitis, inflammatory bowel disease, Crohn's disease, [[or]] ulcerative colitis in a patient comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of 4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,~~

N-{4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-{4-[6-(2-Benzylxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Benzylxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-

4-methyl-benzenesulfonamide,

N-{4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-

phenyl}-4-methyl-benzenesulfonamide,

N-{4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-

methyl-benzenesulfonamide,

N-(3-{6-[4-(Toluene-4-sulfonylamino)-phenylamino]-

pyrimidin-4-yl}-phenyl)-acetamide,

N-{4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-

methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-

phenyl}-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-

ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-

methyl-benzenesulfonamide,

4-Methyl-N-{4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-

ylamino]-phenyl}-benzenesulfonamide,

N-{4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl}-4-

methyl-benzenesulfonamide,

N-{4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-

phenyl}-4-methyl-benzenesulfonamide,

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-

4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-

benzenesulfonamide,

N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-

phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-

benzenesulfonamide,

N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-

methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-

phenyl]-benzenesulfonamide,

N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-

methyl-benzenesulfonamide,

N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-

4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-

phenyl]-benzenesulfonamide

~~or a salt thereof and pharmaceutically acceptable salts~~  
thereof.

**30.** (Currently amended) A compound selected from the group  
consisting of

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-

4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-

benzenesulfonamide,

N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-

phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-

benzenesulfonamide,

N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-

methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-

phenyl]-benzenesulfonamide,

N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-

methyl-benzenesulfonamide,

N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-

4-methyl-benzenesulfonamide, [[and]]

4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-

phenyl]-benzenesulfonamide,

~~or a salt and salts thereof for use in the treatment of~~

~~diseases.~~

31. (Currently amended) Pharmaceutical compositions containing A pharmaceutical composition comprising one or more compounds selected from the group consisting of

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

and pharmaceutically acceptable salts or a salt thereof together with a pharmaceutically acceptable auxiliary

and/or excipient the usual pharmaceutical auxiliaries  
and/or excipients.

32. (Cancel)

33. (Currently amended) A method for treating acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vacular injury, such as angioplasty, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer Alzheimer's disease, [[or]] amyotrophic lateral sclerosis, cancer, infectious diseases, such as AIDS, septic shock [[or]] adult respiratory distress syndrome, ischemia/reperfusion injury, [[e.g.]] myocardial infarction, stroke, gut ischemia, renal failure, [[or]] hemorrhage shock, [[or]] traumatic shock, T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma, [[or]] inflammatory lung injury, inflammatory liver injury, inflammatory

glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, ~~inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, and further eczematous dermatitis, seborrhoeic dermatitis, seborrhoeic dermatitis), inflammatory eye diseases, [[e.g.]] Sjoegren's syndrome, keratoconjunctivitis, [[or]] uveitis, inflammatory bowel disease, Crohn's disease, [[or]] ulcerative colitis in a patient comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,~~

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,  
N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide, [[and]]  
4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,  
~~or a salt thereof~~ and pharmaceutically acceptable salts  
thereof.

JAP18 REC'D PCT/PTO 14 JUL 2006

USSN Not yet assigned

BARSIG, et al.

Page 1 of 1

10/586121

Appendix B

Specification Amendment

Please insert the following into the specification at page 1, line 1:

-- This application was filed under 35 U.S.C. 371 as a national stage of PCT/EP2005/050206, filed January 19, 2005. --

14 JUL 2006

USSN Not yet assigned  
BARSIG, et al.


Page 1 of 1

107586121

Appendix C

Abstract of the Disclosure

Compounds of a certain formula 1



in which R1 and R2 have the meanings indicated in the description are novel kinase inhibitors.